The United States Patent and Trademark Office (USPTO) has published a patent application, US20260083705A1, detailing methods for treating agitation using transdermal delivery patches containing dexmedetomidine. The application was filed on September 24, 2025, by inventors Wan-Ning Song and Gary G. Kay, and includes specific CPC classifications related to drug formulation and therapeutic use.

This publication represents a draft patent application and does not impose any immediate regulatory obligations or compliance deadlines on pharmaceutical companies. However, it signifies potential future intellectual property protection for a novel drug delivery method. Companies operating in the pharmaceutical sector, particularly those involved in developing treatments for agitation or transdermal drug delivery systems, should be aware of this application as it may impact future market exclusivity and competitive landscape.